spacer
home > ebr > Winter 2018
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2018

   
Text
PDF
Editor’s Letter
 
EBR Editor Dr Deborah O’Neil offers a summary of the issue’s contents and comments on the recent breakthrough in treating Huntington’s disease.
 
view
download pdf
bullet
BioResearch and Innovation
Novel Therapies and Pneumococcal Pneumonia
 
Back to the Future
 
Jonas Elliott Gerson, Dr Donald Gerson and Allison Turner at PnuVax SL Biopharmaceuticals detail how pneumococcal pneumonia could be cured in the developing world and the ways in which immunotherapeutic approaches can decrease antimicrobial resistance.
 
view
download pdf
Resistance Rates
 
Situation Critical
 
AMR Centre’s Dr Peter Jackson argues for a greater effort to combat antimicrobial resistance – a serious menace to public health that contributes to over 700,000 deaths globally.
 
view
download pdf
Antiseptics and Antibiotics
 
Fight Against Resistance
 
Antimicrobial resistance in humans and animals is raised through improper use of antibiotics or not controlling infection well enough. Dr Michele Barbour at Pertinax Pharma believes behavioural science should be employed
 
view
download pdf
Competency-Based Training
 
Training Day
 
Dr John Milne at the National Institute for Bioprocessing Research and Training demonstrates how competency-based training will be pivotal to improving the work of staff, with the rise of new types of product and manufacturing processes.
 
view
download pdf
bullet
Discovery Technology
Strategies to Mitigate Risk
 
Constant Vigilance
 
Tony Clarke at ICON delves into how anticipating risk management and ensuring safe design when employing connected medical devices during product lifecycles can lower financial and medical risks.
 
view
download pdf
BioDiscovery
New Treatments
 
Bridging the Gap
 
Dr Gregory R Stewart at Pairnomix posits, by way of a case study, that today’s advancements in genetics can reduce the delay between gene discovery and its use in real world treatments.


 
view
download pdf
BioDevelopment
Contamination Risk Management Strategies for ATMPs
 
Keeping It Clean
 
With the viral safety of biological medicinal products in regenerative medicine being essential, well-characterised cell banks can help avoid contamination and maintain quality, as Andy Bailey at ViruSure notes.
 
view
download pdf
bullet
Biodevelopment and Manufacturing
Patient Safety
 
Warning Letters
 
An unusual amount of warning letters issued by the FDA show that the manufacturing process is being increasingly monitored, as discussed by Søren Lund Kristensen and Dr Harm Otten at Particle Analytical.
 
view
download pdf
bullet
THERAPEUTICS FOCUS - VACCINES AND INFECTIOUS DISEASES
VLP-Based Polio Vaccine
 
Particle Acceleration
 
Methods employed in cryo-electron microscopy help to characterise the structure of new polio vaccines, as outlined by Professor Dave Stuart at Diamond Light Source.
 
view
download pdf
Lifesaving New Vaccines

Gut Feeling
 
Björn Sjöstrand at Scandinavian Biopharma details how new vaccines are being tested in clinical trials to combat the virulence of Enterotoxigenic Escherichia coli in the developing world.
 
view
download pdf
bullet
Drug Discovery
Sophisticated Drug Development
 
Under Lock and Key
 
Dr Misha Kapushesky at Genestack warns that, to maintain their integrity, a higher level of sophistication is needed in data management systems, especially as drug development agreements become more popular.

 
view
download pdf
Collaborating in Data Management
 
Discovery Decisions
 
To guarantee good data management, software creators must collaborate as much as possible with project leaders and decision makers to give them easy access to data. Dr Matthew Segall and Dr Chris Leeding at Optibrium explain.

 
 
view
download pdf
bullet
LICENSING AND REGULATORY
Q&A: Data Compliance
 
Utmost Integrity


EBR
asks Darren Barrington-Light at Thermo Fisher Scientific and Brian Alliston at Sterling Pharma Solutions to elaborate on the ways to achieve data integrity compliance using chromatography data systems.
 
view
download pdf
Global Compliance
 
Regional Requirements
 
Life sciences companies are making the most of globalisation and the standardisation of submission requirements. Key differences remain in regulatory needs between regions, as argued by Kimty Bui-Van at ProductLife Group.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Three-dimensional Cell Culture
 
Cell-ebration
 
Professor Fredrik Johansson at Lund University and Maximilian Ottosson at Cellevate look over the systems utilised when researching three-dimensional cell culture.



 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

When space is tight

Existing packaging lines can be retrofitted for serialization tasks, achieving a maximum of space savings and process reliability: if required, the system comes with an integrated checkweigher and tamper-evident labeler.  
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement